Written by Samantha Farpour, L26 Introduction One-in-eight, or about 13%, of American adults have used a GLP-1 receptor agonist drug (GLP-1 RA), with higher percentages of younger adults using the drugs primarily for weight loss as compared to adults ages sixty-five years and older
The strongest prevention framework is risk reduction across multiple systems: blood pressure control, lipid and cardiometabolic risk management, physical activity, resistance training, sleep quality, hearing and vision support, glucose regulation, alcohol moderation, social connection, and treatment of relevant medical conditions
Due to ongoing supply constraints, off-label prescribing of Ozempic for weight management is not currently recommended in the UK
In conclusion GLP-1 patches are not approved or legitimate weight loss medications